Short Interest in Ascendis Pharma A/S (NASDAQ:ASND) Grows By 5.6%

Ascendis Pharma A/S (NASDAQ:ASND) saw a significant growth in short interest in November. As of November 30th, there was short interest totalling 3,770,000 shares, a growth of 5.6% from the November 15th total of 3,570,000 shares. Based on an average daily volume of 587,700 shares, the short-interest ratio is presently 6.4 days.

Ascendis Pharma A/S Trading Up 5.2 %

Shares of ASND stock opened at $136.60 on Tuesday. The company has a market cap of $8.28 billion, a P/E ratio of -16.91 and a beta of 0.67. The firm has a fifty day moving average price of $129.10 and a 200 day moving average price of $132.72. Ascendis Pharma A/S has a 12 month low of $111.09 and a 12 month high of $161.00.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in ASND. Exome Asset Management LLC lifted its stake in Ascendis Pharma A/S by 119.2% during the third quarter. Exome Asset Management LLC now owns 43,849 shares of the biotechnology company’s stock worth $6,547,000 after purchasing an additional 23,849 shares during the last quarter. Wilmington Savings Fund Society FSB acquired a new stake in Ascendis Pharma A/S during the third quarter worth approximately $30,000. Frazier Life Sciences Management L.P. purchased a new stake in shares of Ascendis Pharma A/S during the 3rd quarter worth approximately $19,908,000. Public Employees Retirement System of Ohio acquired a new position in shares of Ascendis Pharma A/S in the 3rd quarter valued at $1,101,000. Finally, Groupama Asset Managment acquired a new position in shares of Ascendis Pharma A/S in the 3rd quarter valued at $60,000.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on ASND shares. Wells Fargo & Company raised their target price on Ascendis Pharma A/S from $264.00 to $289.00 and gave the company an “overweight” rating in a report on Tuesday, September 17th. Bank of America raised their price objective on shares of Ascendis Pharma A/S from $175.00 to $191.00 and gave the company a “buy” rating in a research note on Monday, September 23rd. Citigroup upped their target price on shares of Ascendis Pharma A/S from $178.00 to $207.00 and gave the stock a “buy” rating in a research note on Tuesday, September 17th. Evercore ISI raised their price target on shares of Ascendis Pharma A/S from $191.00 to $205.00 and gave the company an “outperform” rating in a research report on Tuesday, September 17th. Finally, TD Cowen cut their price objective on Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating on the stock in a research report on Friday, November 15th. Two investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $191.77.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.